Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02300961 · ClinicalTrials.gov registry record · NA

Feasibility Neurocognitive Outcome After Transplant

A NA study of Acute Lymphoblastic Leukemia and Pediatric Cancer, sponsored by Stanford University.

Active
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT02300961: Active NA study of Acute Lymphoblastic Leukemia and Pediatric Cancer, sponsored by Stanford University.

NCT02300961 is a NA study of Acute Lymphoblastic Leukemia and Pediatric Cancer that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 17 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02300961, a NA study of Acute Lymphoblastic Leukemia and Pediatric Cancer, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.

Primary Outcome

Number of participants who enroll in and are able to complete the neurocognitive intervention program, measured at 3 months after enrollment.

Interventions

  • BEHAVIORAL Cognitive rehabilitation program

Study Locations (1)

California

  • Stanford University, School of Medicine - Palo Alto

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2014-12-01
Est. Completion 2025-11
Phase NA
Stanford University

1,744 total trials

What the registry record for NCT02300961 still lists

NCT02300961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Cognitive rehabilitation program is the first listed.

NCT02300961 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02300961 about?

NCT02300961 is a clinical study titled "Feasibility Neurocognitive Outcome After Transplant". This pilot study will primarily be evaluated by feasibility and adherence to an iPad-based neurocognitive intervention program. It will secondarily be evaluated by performance on the neurocognitive testing post-transplant and change in performance in subsequent years.

What is the current status of trial NCT02300961?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2014-12-01. Estimated completion is 2025-11.

What conditions does trial NCT02300961 study?

This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Pediatric Cancer, Stem Cell Transplantation.

What interventions are being tested in trial NCT02300961?

The interventions under investigation include: Cognitive rehabilitation program (BEHAVIORAL).

Who is sponsoring clinical trial NCT02300961?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02300961 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02300961's enrollment target sits among peer trials

17 110th of 131 higher than 20 of 131 other Acute Lymphoblastic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02300961, the US trial registry maintained by the National Library of Medicine. NCT02300961 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.